The fight against COVID-19 continues to evolve as new variants emerge and public health priorities adapt. A recent publication, “Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccines,” offers encouraging insight into how Moderna’s next-generation vaccines perform against the LP.8.1 subvariant and other circulating strains. DelRicht Research investigator Dr. Robert Springer of Springer Wellness and Restorative Health in Atlanta, GA, served as a principal investigator and contributing author on this important advancement in COVID-19 vaccine research.

About the Study

This Phase 3b/4 research evaluated the immunogenicity and safety of two LP.8.1-containing vaccines, mRNA-1273.251 (50 µg) and mRNA-1283.251 (10 µg), in adults aged 12-64 years at high risk for severe COVID-19 and individuals aged ≥65 years. The study was conducted as two independent, open-label, single-arm trials, with participants receiving a single dose of their assigned vaccine and followed through Day 29 post-vaccination. Neutralizing antibodies were measured at baseline and on Day 29, assessing immune responses against the vaccine-matched LP.8.1 variant as well as emerging variants, including BA.3.2.2, XFG, and NB.1.8.1. Unsolicited adverse events, serious events, and events of special interest were monitored throughout the study.

Key Findings

The LP.8.1-containing vaccines demonstrated robust immunogenicity and a favorable safety profile:

– Both vaccines elicited strong Day 29 neutralizing antibody responses against LP.8.1 across age groups.

– Immunogenicity was maintained against circulating variants, with model-based analyses consistent with observed clinical data.

– No vaccine-related adverse events were reported, supporting the safety of both mRNA-1273.251 and mRNA-1283.251.

Predictive modeling indicated that BA.3.2.2 carried the highest relative risk of immune escape following vaccination with mRNA-1273.251, underscoring the importance of ongoing variant-adapted vaccine research.

Dr. Springer’s Impact

With 22+ years of clinical expertise and a strong track record in vaccine trials, Dr. Robert Springer continues to advance public health through high-quality clinical research. His dual role as principal investigator and contributing author on this study exemplifies his dedication to generating meaningful, actionable data that informs both healthcare providers and public health decision-making.

Collaborative Efforts and Leadership

We also commend Stéphane Bancel and the Moderna team for their leadership in adapting mRNA platforms to address emerging COVID-19 variants. Their work, alongside dedicated investigators and site teams, ensures rigorous, evidence-based approaches to vaccination strategy and public health protection.

Explore the Full Publication

Read the full preprint, “Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccines,” on medRxiv.

At DelRicht Research, we are proud to support investigators like Dr. Springer who are helping move the science of infectious disease and vaccine development forward. Through collaboration, innovation, and patient-centered research, we remain committed to generating data that strengthens public health and informs real-world solutions for communities across the country.